Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug5175 | rHuEPO Wiki | 1.00 |
| drug3734 | Roxadustat Wiki | 1.00 |
| drug531 | BNT162b2 Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D051436 | Renal Insufficiency, Chronic NIH | 0.32 |
| D007674 | Kidney Diseases NIH | 0.24 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001903 | Anemia HPO | 1.00 |
| HP:0012622 | Chronic kidney disease HPO | 0.32 |
| HP:0000077 | Abnormality of the kidney HPO | 0.24 |
Navigate: Correlations HPO
There is one clinical trial.
This is a Phase IV, randomized, active-controlled, open-label, parallel design, multicenter prospective study to evaluate the effect of roxadustat versus rHuEPO treatment on the gastrointestinal (GI) iron absorption in patients with anemia of Stage 4 and Stage 5 CKD. This study is planned to screen approximately 104 patients and randomize a minimum of 46 patients (maximum 60) with anemia of CKD from approximately 7 to 10 sites in China.
Description: Evaluation of main effect of roxadustat versus rHuEPO on GI iron absorption.
Measure: Difference from baseline to Day 15 in log-transformed area under curve (AUC) of GI iron absorption (0-3 hours) Time: From baseline (Day 1) to Day 15Description: Assessment of effect and interaction with baseline variables of roxadustat versus rHuEPO on iron absorption.
Measure: Difference from baseline to Day 15 in log-transformed AUC of iron absorption (0-3 hours) Time: From baseline (Day 1) to Day 15Description: Assessment of effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: serum iron.
Measure: Difference from baseline to Day 15 in serum iron Time: From baseline (Day 1) to Day 15Description: Assessment of effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: ferritin.
Measure: Difference from baseline to Day 15 in ferritin Time: From baseline (Day 1) to Day 15Description: Assessment of effect and interaction with key baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: TIBC.
Measure: Difference from baseline to Day 15 in total iron binding capacity (TIBC) Time: From baseline (Day 1) to Day 15Description: Assessment of effect and interaction with key baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: TSAT.
Measure: Difference from baseline to Day 15 in transferrin saturation (TSAT) Time: From baseline (Day 1) to Day 15Description: Assessment of effect and interaction with key baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: transferrin.
Measure: Difference from baseline to Day 15 in transferrin Time: From baseline (Day 1) to Day 15Description: Assessment of effect and interaction with key baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: soluble transferrin receptor.
Measure: Difference from baseline to Day 15 in soluble transferrin receptor Time: From baseline (Day 1) to Day 15Description: Assessment of effect and interaction with key baseline variables of roxadustat versus rHuEPO on hepcidin levels.
Measure: Difference from baseline to Day 15 in hepcidin levels Time: From baseline (Day 1) to Day 15Description: Assessment of safety by incidence of AEs, and measurement of vital signs (tympanic temperature, blood pressure (BP), pulse and respiratory rate), laboratory variables
Measure: Number of patients with adverse events (AEs) and serious adverse events (SAEs) Time: From Screening to 28-day Follow-up Period (Approximately 9 Weeks)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports